7-BROMO-5-(4-CHLOROBENZYL)-3-PROPYLISOXAZOLO[4,5-D]PYRIDAZIN-4(5H)-ONE

Catalog No. :
ACVOBB979
CAS No. :
2088729-56-8
Molecular Formula :
C15H13BrClN3O2
Molecular Weight :
382.64

IUPAC Name:7-bromo-5-(4-chlorobenzyl)-3-propylisoxazolo[4,5-d]pyridazin-4(5H)-one

7-BROMO-5-(4-CHLOROBENZYL)-3-PROPYLISOXAZOLO[4,5-D]PYRIDAZIN-4(5H)-ONE structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$511.00Login to see priceInquiryInquiry
1g95%$1280.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-BROMO-5-(4-CHLOROBENZYL)-3-PROPYLISOXAZOLO[4,5-D]PYRIDAZIN-4(5H)-ONE
IUPAC Name7-bromo-5-(4-chlorobenzyl)-3-propylisoxazolo[4,5-d]pyridazin-4(5H)-one
MDL No.MFCD31556735
Molecular FormulaC15H13BrClN3O2
Molecular Weight382.64
SMILESO=C1C2=C(C(Br)=NN1CC3=CC=C(C=C3)Cl)ON=C2CCC
InChI KeyNJXCSPFGPXYHFW-UHFFFAOYSA-N
Synonym7-Bromo-5-(4-chlorobenzyl)-3-propylisoxazolo[4,5-D]pyridazin-4(5H)-one;Isoxazolo[4,5-d]pyridazin-4(5H)-one, 7-bromo-5-[(4-chlorophenyl)methyl]-3-propyl-
CAS No.2088729-56-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACVOBB979 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVOBB979 route product structure diagram
    ACVOBB9792088729-56-8
Inquiry

2. ACVOBB979 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVOBB979 route product structure diagram
    ACVOBB9792088729-56-8
Inquiry

Comments (0)